[
    [
        {
            "time": "",
            "original_text": "沃森生物：CEPI于近日宣布将向公司控股子公司上海泽润生物科技有限公司提供1310万美元的资金资助，用于相关产品的研发和临床研究",
            "features": {
                "keywords": [
                    "沃森生物",
                    "CEPI",
                    "上海泽润",
                    "资金资助",
                    "产品研发",
                    "临床研究"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "沃森生物：CEPI于近日宣布将向公司控股子公司上海泽润生物科技有限公司提供1310万美元的资金资助，用于相关产品的研发和临床研究",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "“放弃”科创板转港股，又被发回，艾美疫苗成色受质疑，九成营收靠两款“老产品”",
            "features": {
                "keywords": [
                    "艾美疫苗",
                    "科创板",
                    "港股",
                    "营收",
                    "老产品"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "“放弃”科创板转港股，又被发回，艾美疫苗成色受质疑，九成营收靠两款“老产品”",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "沃森生物成立医药技术公司，注册资本5000万",
            "features": {
                "keywords": [
                    "沃森生物",
                    "医药技术公司",
                    "注册资本"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "沃森生物成立医药技术公司，注册资本5000万",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：本周医药跌幅居前 建议关注市场波动下疫苗板块机会",
            "features": {
                "keywords": [
                    "医药行业",
                    "周报",
                    "跌幅",
                    "疫苗板块",
                    "市场波动"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药行业周报：本周医药跌幅居前 建议关注市场波动下疫苗板块机会",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药周刊 | 罗氏制药中国总裁周虹将加入默克；阿斯利康完成收购亚力兄；国药疫苗对变异新冠病毒有效",
            "features": {
                "keywords": [
                    "罗氏制药",
                    "默克",
                    "阿斯利康",
                    "亚力兄",
                    "国药疫苗",
                    "变异新冠病毒"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药周刊 | 罗氏制药中国总裁周虹将加入默克；阿斯利康完成收购亚力兄；国药疫苗对变异新冠病毒有效",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]